口服异二因及其在皮肤病学中的用途:一篇综述
Anon Paichitrojjana1, Anand Paichitrojjana2
1School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok, Thailand.
Drug design, development and therapy
|August 31, 2023
概括
伊索特里诺因被批准用于治疗严重的,由于其抗炎性质,它也被用于治疗各种皮肤疾病. 本审查审查了证据证明其在皮肤病学中的适当使用.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 维生素A的衍生物伊索特里诺因 (13-cis-retinoic acid) 在1982年被FDA批准用于治疗严重的复发性.
- 它的抗炎症,免疫调节和抗性质支持在轻度至中度,基因皮肤病,皮肤癌和其他皮肤疾病的非标签使用.
研究的目的:
- 审查有关口服异二因的皮肤病应用的最新基于证据的数据.
- 为临床医生提供必要的信息,以便他们能够就异二因使用做出明智的决定.
主要方法:
- 对当前文献进行系统审查.
- 基于证据的数据分析,分析了口服异丁在各种皮肤病的疗效和安全性.
主要成果:
- 伊索特里诺因在某些非标签用途中表现出有效性,而其他用途则表现出有限的有效性.
- 临床数据突出显示,异氨酸在治疗各种皮肤疾病方面具有多样化的结果.
结论:
- 口服异二胺已在治疗严重的疗效和在其他皮肤病的潜在效用方面得到证实.
- 需要进一步的研究和仔细的临床判断,以优化异氨酸的非标签应用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
697
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
697
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152


